ArticleOcular oncology and pathology2024
Clinical Features and Initial Management Outcomes of Uveal Melanomas in a Single Tertiary Center in Egypt.
Article in Ocular oncology and pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We aimed to report the demographic data, clinical features, and management outcomes of patients with uveal melanoma (UM) in a single tertiary center in Egypt. Methods: This is a single-center retrospective case series. Patients with UM who were managed at Cairo University Ocular Oncology Service between January 2019 and December 2023 were included. Records were analyzed for patients' demographics, clinical features and different management options. Outcomes included changes in best corrected visual acuity and tumor dimensions (thickness and largest base diameter), perioperative complications, globe salvage, and recurrence rates. Results: A total of 93 eyes of 93 patients with UM were treated in our service over a period of 5 years. The mean age of patients was 52.18 ± 13.30 years, and 91.4% of tumors were choroidal or ciliochoroidal. 52 eyes (55.91%) were managed with ruthenium-106 episcleral brachytherapy, of which two eyes required additional brachytherapy, 8 eyes ended with secondary enucleation, and the globe was salvaged in 84.62% of eyes. 8 eyes (8.60%) were managed by gamma knife radiosurgery with or without endoresection. One eye with an iridociliary tumor was managed with partial lamellar sclerouvectomy, and the remaining 32 eyes (34.41%) were primarily enucleated. Conclusion: Timely referral channels and accurate assessment of cases with UM are invaluable for achievement of higher success rates in tumor regression, as well as globe and/or vision salvage in eyes managed with brachytherapy. Patients with more advanced tumors should be counseled on the importance of more invasive options such as enucleation in achieving lower metastasis and mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.